An advisory panel to the Food and Drug Administration voted against a similar request from Pfizer in mid-September, but the agency is considered likely to grant the request, perhaps before Thanksgiving.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
